论文部分内容阅读
目的 :通过对肿瘤患者服用阿托氟啶后的药代动力学研究 ,探讨阿托氟啶在人体内的药代动力学特征。方法 :18例恶性肿瘤患者随机分成 3组 ,分别po阿托氟啶 80 0 ,10 0 0和 12 0 0mg ,采用高效液相色谱法测定用药后不同时间血清中阿托氟啶代谢产物的浓度 ,并对所测得的血药浓度 时间数据进行拟合 ,计算药代动力学参数。结果 :阿托氟啶在人体内的代谢物为 3 邻甲基苯甲酰基 5 氟尿嘧啶 (TFU) ,后者在体内的代谢符合一房室模型的特征。不同患者对阿托氟啶的代谢存在较大的个体差异。高中低剂量组的阿托氟啶的药代动力学参数没有显著性差异。结论 :阿托氟啶的体内代谢存在极大的个体差异 ,有必要进行治疗药物监测 ,实现临床用药个体化。
OBJECTIVE: To investigate the pharmacokinetics of atofluidide in human patients by pharmacokinetic study of atorvastatin in patients with cancer. Methods: Twenty-eight patients with malignant tumor were randomly divided into three groups: po Atorvastatin 80 0, 100 0 and 120 mg respectively. The concentrations of the metabolites of atropuridine in serum at different time points were determined by high performance liquid chromatography , And the measured blood concentration time data were fitted to calculate the pharmacokinetic parameters. Results: Metabolites of atorvastatin in humans were 3-O-methylbenzoyl-5-fluorouracil (TFU), which was metabolized in the body in line with the characteristics of a one-compartment model. There are large individual differences in the metabolism of atofluidide in different patients. There was no significant difference in the pharmacokinetic parameters of atorvastatin in high school and low dose groups. CONCLUSION: There is a great individual difference in the metabolism of atorvastatin in vivo. It is necessary to monitor the therapeutic drugs and achieve individualization of clinical medication.